Selection of Neuroprotective Therapy in Patients with Chronic Cerebral Ischemia Taking Account of the Synergism of Drug Interactions

Objective. To optimize selection of neuroprotective treatment protocols in patients with chronic cerebral ischemia taking account of synergism in drug interactions for an individual personalized approach to increase treatment efficacy. Materials and Methods. Differential chemoreactome analysis of synergism between ethylmethylhydroxypyridine succinate (EMHPS) and a number of single-component neuroprotective substances (piracetam, vinpocetine, citicoline, choline alfoscerate); proteome analysis of polypeptide neuroprotectors (Cerebrolysin and others); expert analysis of the composition of a multicomponent neuroprotector (Cytoflavin). Results. Piracetam, citicoline (Neupilept), and choline alfoscerate (Cereton) effectively enhanced the pharmacological properties of EMHPS. Expert assessments of synergism between the properties of EMHPS, polypeptide neuroprotectors (Cerebrolysin), and other multicomponent formulations (Cytoflavin), which are also used in the adjuvant therapy in combination with EMHPS, are presented. Conclusions. In real clinical practice there is particular interest in objective evaluation of combined treatment protocols. EMHPS can provide a favorable background for maximizing treatment efficacy using additional drugs.